Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.64 |
| ▸ | STAT1 | P42224 | 1/20 | 0.64 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584789 | 0.97 | STAT3 (0.67) | STAT3STAT1MGAMGAASI | |
| SCHEMBL29403134 | 0.85 | STAT3 (0.64) | STAT3STAT1TOP1TERTCYCS | |
| SCHEMBL3352961 | 0.85 | STAT3 (0.64) | STAT3STAT1TOP1TERTCYCS | |
| SCHEMBL473158 | 0.85 | STAT3 (0.86) | STAT3STAT1TOP1TERTCYCS | |
| SCHEMBL6803313 | 0.85 | STAT3 (0.63) | STAT3STAT1TOP1TERTCYCS | |
| SCHEMBL30753635 | 0.85 | STAT3 (0.86) | STAT3STAT1TOP1TERTCYCS | |
| SCHEMBL6033674 | 0.85 | STAT3 (0.64) | STAT3STAT1TOP1TERTCYCS | |
| SCHEMBL29402399 | 0.84 | STAT3 (0.63) | STAT3STAT1TOP1TERTCYCS | |
| SCHEMBL28459011 | 0.84 | STAT3 (0.63) | STAT3STAT1TOP1TERTCYCS | |
| SCHEMBL14973450 | 0.84 | STAT3 (0.63) | STAT3STAT1TOP1TERTCYCS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119223945-A | High-temperature Daqu liquor identification method based on porphyrin catalyst quasi-peroxidase activity oxidation TMB color change | 中南民族大学 | 2024-12-31 | — | — | CN | claimed |
| CN-118555971-A | Amorphous photosensitive particles, methods of making and methods of using the same | 马里兰大学帕克分校 | 2024-08-27 | — | — | CN | claimed |
| CN-112940268-B | Interface in-situ growth metal-organic framework material and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2022-04-12 | — | — | CN | claimed |
| CN-112940268-A | Interface in-situ growth metal-organic framework material and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2021-06-11 | — | — | CN | claimed |
| US-9211283-B2 | Nanoparticle carrier systems based on human serum albumin for photodynamic therapy | BIOLITEC PHARMA MARKETING LTD (MY) | 2015-12-15 | — | — | US | claimed |
| CN-1605026-A | Electrode for active oxygen species and sensor using the electrode | MAKOTO YUASA (JP) | 2005-04-06 | — | — | CN | claimed |
| EP-1263761-B1 | COMPOUNDS FOR PDT | BIOLITEC PHARMA MARKETING LTD (MY) | 2004-12-01 | — | — | EP | claimed |
| EP-0337601-B1 | PORPHYRINS AND MEDICAMENTS FOR CANCER TREATMENT | SCOTIA HOLDINGS PLC (GB) | 1993-05-05 | — | — | EP | claimed |
| CN-119223945-A | High-temperature Daqu liquor identification method based on porphyrin catalyst quasi-peroxidase activity oxidation TMB color change | 中南民族大学 | 2024-12-31 | — | — | CN | disclosed |
| CN-118555971-A | Amorphous photosensitive particles, methods of making and methods of using the same | 马里兰大学帕克分校 | 2024-08-27 | — | — | CN | disclosed |
| CN-109922834-B | Porphyrin compounds and compositions for the treatment of cancer | 良药治疗公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-112940268-B | Interface in-situ growth metal-organic framework material and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2022-04-12 | — | — | CN | disclosed |
| CN-112940268-A | Interface in-situ growth metal-organic framework material and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2021-06-11 | — | — | CN | disclosed |
| EP-2509633-A2 | NANOPARTICLE CARRIER SYSTEMS BASED ON POLY(DL-LACTIC-CO-GLYCOLIC ACID) (PLGA) FOR PHOTODYNAMIC THERAPY (PDT) | CeramOptec GmbH (DE) | 2012-10-17 | — | — | EP | disclosed |
| CN-102256622-A | Calciumphosphate-based nanoparticles as carrier-systems for photodynamic therapy | BIOLITEC AG | 2011-11-23 | — | — | CN | disclosed |
| US-20100256136-A1 | Method for Enhancing Pdt Efficacy Using a Tyrosine Kinase Inhibitor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-10-07 | — | — | US | disclosed |
| CN-1605026-A | Electrode for active oxygen species and sensor using the electrode | MAKOTO YUASA (JP) | 2005-04-06 | — | — | CN | disclosed |
| US-20030212052-A1 | Use of ursdeoxycholic acid for potentiation of the phototoxic effect of photodynamic therapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-11-13 | — | — | US | disclosed |
| EP-0820305-A2 | CANCER TREATMENT BY PHOTODYNAMIC THERAPY, IN COMBINATION WITH AN IMMUNOADJUVANT | Wound Healing of Oklahoma (US) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996031237-A2 | CANCER TREATMENT BY PHOTODYNAMIC THERAPY, IN COMBINATION WITH AN IMMUNOADJUVANT | WOUND HEALING OF OKLAHOMA (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256136-A1 | Method for Enhancing Pdt Efficacy Using a Tyrosine Kinase Inhibitor | UROD, SLC7A1, TAP2 | STAT3 967/4885STAT1 1433/4885MGAM 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.